

Qingjuan Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9682201/publications.pdf>

Version: 2024-02-01

11
papers

510
citations

1040056

9
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

913
citing authors

#	ARTICLE	IF	CITATIONS
1	Long noncoding RNAs as tumorigenic factors and therapeutic targets for renal cell carcinoma. <i>Cancer Cell International</i> , 2021, 21, 110.	4.1	9
2	Plasma Long Non-Coding RNA RP11-438N5.3 as a Novel Biomarker for Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 1513-1521.	1.9	17
3	The Oncogenic and Tumor Suppressive Functions of the Long Noncoding RNA MALAT1: An Emerging Controversy. <i>Frontiers in Genetics</i> , 2020, 11, 93.	2.3	53
4	Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. <i>Experimental Cell Research</i> , 2018, 362, 362-369.	2.6	46
5	The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 502.	2.8	67
6	The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. <i>Oncotarget</i> , 2016, 7, 56209-56218.	1.8	92
7	Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer. <i>Oncology Letters</i> , 2016, 12, 1361-1366.	1.8	48
8	Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. <i>Oncology Reports</i> , 2014, 31, 1863-1870.	2.6	89
9	P-Akt/miR-200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells. <i>International Journal of Oncology</i> , 2014, 45, 2430-2438.	3.3	24
10	CD44 acts through RhoA to regulate YAP signaling. <i>Cellular Signalling</i> , 2014, 26, 2504-2513.	3.6	59
11	Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells. <i>Oncology Reports</i> , 2014, 32, 1401-1408.	2.6	6